Adverse effects of COVID-19 pandemic on a multicenter randomized controlled trial

Elie G Abu Jawdeh1, Carl E Hunt2, Eric Eichenwald3

  • 1University of Kentucky, Lexington, KY, USA. elie.abujawdeh@uky.edu.

Insights

The COVID-19 pandemic significantly reduced parent approach for infant consent in a clinical trial, with enrollment rates only partially recovering post-pandemic. Consent rates per approached parent remained stable.

Area of Science:

  • Clinical Trials
  • Epidemiology
  • Public Health

Background:

  • The COVID-19 pandemic presented unprecedented challenges to healthcare systems globally.
  • Clinical trial operations, particularly subject recruitment, were significantly impacted by public health measures and parental concerns.

Purpose of the Study:

  • To evaluate the impact of the COVID-19 pandemic on subject enrollment in a multicenter randomized controlled trial.
  • To assess changes in the ability to approach parents for consent and their subsequent consent rates.

Main Methods:

  • A multicenter randomized controlled trial design was employed.
  • Enrollment data, including the number of eligible infants approached and consented, were analyzed across five distinct epochs: baseline, peak pandemic, and recovery phases.

Main Results:

  • Parental approach rates decreased dramatically from 95.4% at baseline to 13.1% during the peak pandemic.
  • Enrollment recovery was incomplete, with post-pandemic approach rates at 84.9%.
  • Despite reduced approach rates, the consent rate among approached parents remained statistically unchanged.

Conclusions:

  • The COVID-19 pandemic severely hindered the ability to approach parents for infant consent in clinical trials.
  • Partial recovery in approach rates has been observed, but challenges in investigator-parent interactions persist.
  • Maintaining trial integrity requires adaptive strategies to overcome pandemic-related recruitment barriers.
Abstract

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
156